MOTS‑c Peptide — Informed Consent (Research Peptide / Investigational Use)

INFORMED CONSENT FOR MOTS‑c PEPTIDE — RESEARCH/INVESTIGATIONAL USE

§1 PURPOSE, CONTEXT, AND SCOPE

§1.1 This document constitutes an informed consent agreement between the Patient identified herein (the "Patient") and the Prescribing Physician acting on behalf of the Clinic. It is intended to document that the Patient has received, understood, and accepted comprehensive information regarding the proposed use of MOTS‑c, a research/investigational peptide.

§1.2 CRITICAL NOTICE — RESEARCH PEPTIDE: MOTS‑c is a research peptide that has NOT been approved by any regulatory agency (EMA, FDA, or equivalent) for any clinical indication. It is an investigational compound. By proceeding with this consent, the Patient acknowledges the experimental and unregulated nature of this treatment.

§1.4 Health optimization context: The Patient understands that the Clinic operates as a proactive health optimization / longevity practice. The Clinic is not an emergency provider. The Patient is responsible for maintaining an appropriate relationship with a primary care physician and/or relevant specialist(s) for diagnosis and management of disease, acute care, and emergencies.

§1.5 This consent is governed by the laws of Denmark and the European Union, including but not limited to the Danish Health Act (Sundhedsloven) and Regulation (EU) 2016/679 (General Data Protection Regulation).

§1.6 By signing this document, the Patient confirms they have had adequate time to read, consider, and ask questions, and that their questions have been answered to their satisfaction.

§3 COMPOUND DESCRIPTION AND REGULATORY STATUS

§3.1 What is MOTS‑c? MOTS‑c (Mitochondrial Open reading frame of the Twelve S rRNA type‑c) is a mitochondrial‑derived peptide (MDP) — a small signaling molecule encoded within mitochondrial DNA. It was identified in 2015 and has been studied primarily in preclinical (cell and animal) models.

§3.3 REGULATORY STATUS — NOT APPROVED:

  • MOTS‑c is NOT approved by the European Medicines Agency (EMA) for any indication
  • MOTS‑c is NOT approved by the U.S. Food and Drug Administration (FDA) for any indication
  • MOTS‑c is NOT approved by any national regulatory authority for human therapeutic use
  • MOTS‑c is classified as a research chemical/investigational peptide
  • No completed human clinical trials have established safety or efficacy
  • Use in humans is based on preclinical research and anecdotal clinical experience only

§3.4 Manufacturing and quality: The Patient understands that:

  • MOTS‑c is typically obtained from research chemical suppliers or compounding facilities
  • Quality, purity, and consistency may vary between suppliers
  • The Clinic endeavors to use reputable sources with third‑party testing where available, but manufacturing standards may not meet pharmaceutical (GMP) requirements
  • The Patient accepts the risk of product variability and potential contaminants

§4 PROPOSED MECHANISM AND RATIONALE

§4.1 Preclinical research (cell and animal studies) suggests that MOTS‑c may:

  • Influence metabolic pathways, including glucose metabolism and insulin sensitivity
  • Affect mitochondrial function and cellular energy production
  • Have anti‑inflammatory properties
  • Potentially improve exercise capacity and metabolic health in animal models
  • Play a role in aging biology (levels may decline with age in some studies)

§4.2 Intended use in this Clinic: MOTS‑c is being used as part of a health optimization / longevity protocol, with the hypothesis that it may support metabolic function, energy, and mitochondrial health.

§4.3 Critical limitations: The Patient understands that:

  • Almost all evidence comes from cell studies and animal models
  • Translation to humans is uncertain
  • No human clinical trials have established efficacy or optimal dosing
  • Benefits in humans are entirely hypothetical and based on extrapolation

§5 PROPOSED BENEFITS (NO GUARANTEE — HYPOTHETICAL)

§5.1 Based on preclinical research and anecdotal reports (which have significant limitations), proposed potential benefits may include:

  • Improved energy and reduced fatigue
  • Enhanced exercise capacity or recovery
  • Improved metabolic markers (glucose, insulin sensitivity)
  • General sense of well‑being

§5.2 CRITICAL DISCLAIMER: The Patient understands that:

  • These proposed benefits are entirely hypothetical in humans
  • No human clinical trials have demonstrated any of these effects
  • Many patients may experience no benefit whatsoever
  • Benefits cannot be predicted and are not guaranteed
  • The Patient is using this compound with full knowledge that it is experimental

§6 MATERIAL RISKS AND ADVERSE EFFECTS

§6.1 LIMITED SAFETY DATA: The Patient understands that long‑term safety data in humans does not exist. The risks described below are based on limited preclinical data and anecdotal reports.

§6.2 Known or anticipated adverse effects:

  • Injection site reactions (pain, redness, swelling)
  • Nausea or gastrointestinal discomfort
  • Headache
  • Fatigue (paradoxically)
  • Hypoglycemia (theoretical, if metabolic effects are significant)
  • Flushing or warmth

§6.3 Unknown risks: The Patient understands that:

  • Long‑term effects are completely unknown
  • Effects on cancer risk, cardiovascular health, immune function, and other organ systems are unknown
  • Interactions with other medications are unstudied
  • Rare or serious adverse effects may exist but have not been identified due to lack of study
  • The Patient accepts that they are using a compound with an incomplete safety profile

§6.4 Product quality risks: Due to the unregulated nature of research peptides:

  • Contamination with other substances is possible
  • Degradation during storage or shipping is possible
  • Mislabeling or incorrect concentrations are possible
  • Sterility cannot be guaranteed to pharmaceutical standards

§7 CONTRAINDICATIONS AND PRECAUTIONS

§7.1 Due to lack of safety data, the following are general precautions:

  • Active malignancy (theoretical concern; unknown interaction with cancer cell metabolism)
  • Severe diabetes or hypoglycemia tendency (metabolic effects may alter glucose)
  • Known allergy or prior reaction to MOTS‑c or similar peptides
  • Active severe infection
  • Children and adolescents (not studied)

§7.2 The Patient confirms they have disclosed all relevant medical history.

§8 DRUG AND SUPPLEMENT INTERACTIONS

§8.1 Drug interactions with MOTS‑c are unstudied. The Patient understands that:

  • No formal drug interaction studies exist
  • Theoretical interactions with diabetes medications are possible
  • The Patient agrees to inform the Clinic of all medications and supplements
  • The Patient agrees to report any unusual symptoms after starting MOTS‑c

§9 ADMINISTRATION AND DOSING

§9.1 MOTS‑c is typically administered by subcutaneous injection.

§9.2 Dosing: Optimal dosing in humans is unknown. Dosing used in this Clinic is based on preclinical data extrapolation and anecdotal clinical experience.

§9.3 The Patient will be instructed on proper injection technique, reconstitution (if applicable), storage, and disposal of sharps.

§9.4 Storage: MOTS‑c typically requires refrigeration. The Patient agrees to follow storage instructions.

§10 MONITORING

§10.1 No established monitoring protocol exists. Monitoring may include:

  • Clinical assessment of symptoms and tolerability
  • Metabolic markers (fasting glucose, HbA1c, fasting insulin) as part of routine optimization
  • The Patient agrees to report any adverse effects or unusual symptoms promptly

§11 ALTERNATIVE TREATMENTS

§11.1 The Patient has been informed of alternatives, including:

  • Evidence‑based lifestyle interventions (diet, exercise, sleep)
  • Other pharmacological interventions with established safety profiles (e.g., metformin, SGLT2 inhibitors)
  • No treatment with research peptides

§11.2 The Patient understands that evidence‑based alternatives with known safety profiles exist and has chosen to proceed with MOTS‑c.

§13 LIMITATION OF LIABILITY / NO GUARANTEE

§13.1 The Patient understands that MOTS‑c is a research compound with no regulatory approval and accepts the experimental nature of its use.

§13.2 The Patient understands that:

  • Benefits are entirely hypothetical and not guaranteed
  • Long‑term safety is unknown
  • Adverse effects may occur that have not been identified
  • The Clinic makes no representation about the efficacy of this compound

§13.3 The Patient accepts responsibility for the decision to use an unapproved research compound.

§13.4 Nothing in this consent excludes liability that cannot be excluded under applicable Danish law.

§14 WITHDRAWAL OF CONSENT

§14.1 The Patient may withdraw consent and discontinue use at any time.

§15 DATA PROTECTION

§15.1 The Patient's personal data will be processed in accordance with GDPR.

§16 ACKNOWLEDGMENTS AND DECLARATIONS

By consenting, the Patient confirms the following:

  • I have read this consent document in its entirety and understand its contents.
  • I understand that MOTS‑c is a RESEARCH PEPTIDE with NO REGULATORY APPROVAL for any clinical indication.
  • I understand that NO HUMAN CLINICAL TRIALS have established safety or efficacy.
  • I understand that all proposed benefits are HYPOTHETICAL and based on preclinical research only.
  • I understand that LONG‑TERM SAFETY DATA DOES NOT EXIST.
  • I understand that manufacturing quality may not meet pharmaceutical standards.
  • I understand the risks of product contamination, degradation, or variability.
  • I accept the experimental nature of this treatment and the unknowns involved.
  • I understand that evidence‑based alternatives exist and have chosen to proceed with MOTS‑c.
  • I have disclosed all relevant medical history and current medications.
  • I understand I must seek emergency care for severe symptoms.
  • I have had the opportunity to ask questions and my questions were answered.
  • I voluntarily consent to use the prescribed medication understanding its research/investigational status.